
Journal Menu
► ▼ Journal Menu-
- Pharmaceutics Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserNeed Help?
Announcements
28 July 2025
World Hepatitis Day—“Hepatitis: Let’s Break It Down”, 28 July 2025

World Hepatitis Day is observed each year on 28 July to raise awareness of viral hepatitis, a type of inflammation of the liver that causes severe liver disease and liver cancer.
The theme for 2025—“Hepatitis: Let’s Break It Down”—calls for urgent action to dismantle the financial, social and systemic barriers, including stigma, that stand in the way of hepatitis elimination and liver cancer prevention.
Chronic hepatitis B and C silently cause liver damage and cancer—despite them being preventable, treatable, and, in the case of hepatitis C, curable. The theme emphasizes the need to simplify, scale up, and integrate hepatitis services—vaccination, safe injection practices, harm reduction and especially testing and treatment—into national health systems.
The campaign is a reminder that we must act now to expand access, integrate care, and end hepatitis as a public health problem by 2030.
In recognition of this important day, we recommend the following related articles, Special Issues, and journals spanning multidisciplinary fields, including clinical medicine. We believe that promoting such research contributes to enhanced public awareness and a greater understanding of viral hepatitis, an inflammation of the liver that causes severe liver disease and liver cancer.

Biology & Life Sciences |
Medicine & Pharmacology |

“Curcumin Nanocarriers in the Protection Against Iron- and Alcohol-Induced Oxidative Stress in a Cellular Model of Liver Disease”
by Lucy Petagine, Mohammed G. Zariwala, Satyanarayana Somavarapu, Stefanie Ho Yi Chan and Vinood B. Patel
Biology 2025, 14(5), 455; https://doi.org/10.3390/biology14050455
“Hepatic Estrogen Receptor Alpha Overexpression Protects Against Hepatic Insulin Resistance and MASLD”
by Ester S. Alves, Jessica D. M. Santos, Alessandra G. Cruz, Felipe N. Camargo, Carlos H. Z. Talarico, Anne R. M. Santos, Carlos A. A. Silva, Henrique J. N. Morgan, Sandro L. Matos, Layanne C. C. Araujo et al.
Pathophysiology 2025, 32(1), 1; https://doi.org/10.3390/pathophysiology32010001
“Change in Estimated Glomerular Filtration Rate After Direct-Acting Antiviral Treatment in Chronic Hepatitis C Patients”
by Gantogtokh Dashjamts, Amin-Erdene Ganzorig, Yumchinsuren Tsedendorj, Dolgion Daramjav, Enkhmend Khayankhyarvaa, Bolor Ulziitsogt, Otgongerel Nergui, Ganchimeg Dondov, Tegshjargal Badamjav, Tulgaa Lonjid et al.
Diseases 2025, 13(2), 26; https://doi.org/10.3390/diseases13020026
“Effects of SARS-CoV-2 Spike S1 Subunit on the Interplay Between Hepatitis B and Hepatocellular Carcinoma Related Molecular Processes in Human Liver”
by Giovanni Colonna
Livers 2025, 5(1), 1; https://doi.org/10.3390/livers5010001
“Liver Cancer Neuroscience: Regulating Liver Tumors via Selective Hepatic Vagotomy”
by Kylynda C. Bauer, Shadin Ghabra, Chi Ma Lee Chedester and Tim F. Greten
Methods Protoc. 2024, 7(6), 99; https://doi.org/10.3390/mps7060099
“Role of Circulating microRNAs in Liver Disease and HCC: Focus on miR-122”
by Francesco Colaianni, Veronica Zelli, Chiara Compagnoni, Martina Sara Miscione, Mario Rossi, Davide Vecchiotti, Monica Di Padova, Edoardo Alesse, Francesca Zazzeroni and Alessandra Tessitore
Genes 2024, 15(10), 1313; https://doi.org/10.3390/genes15101313
“Impact of Hepatitis Delta Virus Infection on the Selection of Hepatitis B Surface Antigen Mutations”
by Kabo Baruti,Wonderful T. Choga, Bonolo B. Phinius, Basetsana Phakedi, Lynnette Bhebhe, Gorata G. A. Mpebe, Patience C. Motshosi, Tsholofelo Ratsoma, Sikhulile Moyo, Mosimanegape Jongman et al.
Genes 2024, 15(8), 982; https://doi.org/10.3390/genes15080982
“NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options”
by Natalia G. Vallianou, Dimitris Kounatidis, Sotiria Psallida, Nikolaos Vythoulkas-Biotis, Andreas Adamou, Tatiana Zachariadou, Sofia Kargioti, Irene Karampela and Maria Dalamaga
Metabolites 2024, 14(7), 366; https://doi.org/10.3390/metabo14070366
“miRNA Expression and HCC Occurrence in HCV Cirrhotic Patients Treated with Direct Acting Antivirals”
by Antonietta Romano, Alessandra Brocca, Zoe Mariño, Sofía Pérez-del-Pulgar, Sabela Lens, Loreto Boix, María Reig, Jordi Bruix, Giulio Ceolotto, Valeria Calvino et al.
Livers 2024, 4(2), 275-286; https://doi.org/10.3390/livers4020020
“The Full-Genome Analysis and Generation of an Infectious cDNA Clone of a Genotype 6 Hepatitis E Virus Variant Obtained from a Japanese Wild Boar: In Vitro Cultivation in Human Cell Lines”
by Putu Prathiwi Primadharsini, Masaharu Takahashi, Tsutomu Nishizawa, Yukihiro Sato, Shigeo Nagashima, Kazumoto Murata and Hiroaki Okamoto
Viruses 2024, 16(6), 842; https://doi.org/10.3390/v16060842
“Hepatitis C Prevalence and Birth Outcomes among Pregnant Women in the United States: A 2010–2020 Population Study”
by Paul Wasuwanich, Songyos Rajborirug, Robert S. Egerman, Tony S. Wen and Wikrom Karnsakul
Pathogens 2024, 13(4), 321; https://doi.org/10.3390/pathogens13040321
“Prospects for Controlling Hepatitis B Globally”
by Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral and Carmen de Mendoza
Pathogens 2024, 13(4), 291; https://doi.org/10.3390/pathogens13040291
“Longterm Outcome of Therapeutic Vaccination with a Third Generation Pre-S/S HBV Vaccine (PreHevbrioR) of Chronically HBV Infected Patients”
by Hedwig Roggendorf, Daniel Shouval, Michael Roggendorf and Guido Gerken
J. Pers. Med. 2024, 14(4), 364; https://doi.org/10.3390/jpm14040364
“NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay”
by Simona Cernea
Life 2024, 14(2), 272; https://doi.org/10.3390/life14020272
“Updated Clinical Guidelines on the Management of Hepatitis C Infection in Children”
by Chaowapong Jarasvaraparn, Christopher Hartley and Wikrom Karnsakul
Pathogens 2024, 13(2), 180; https://doi.org/10.3390/pathogens13020180
“Non-Invasive Assessment of Liver Fibrosis in Hepatitis B Patients”
by Chinmay Bera, Nashla Hamdan-Perez and Keyur Patel
J. Clin. Med. 2024, 13(4), 1046; https://doi.org/10.3390/jcm13041046
“Real-World Utilization of Corticosteroids in Severe Alcoholic Hepatitis: Eligibility, Response, and Outcomes”
by Ana-Maria Singeap, Horia Minea, Oana Petrea, Madalina-Andreea Robea, Ioana-Miruna Balmuș, Raluca Duta, Ovidiu-Dumitru Ilie, Carmen Diana Cimpoesu, Carol Stanciu and Anca Trifan
Medicina 2024, 60(2), 311; https://doi.org/10.3390/medicina60020311
“Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview”
by Lydia A. Mercado, Fernando Gil-Lopez, Razvan M. Chirila and Denise M. Harnois
Diagnostics 2024, 14(4), 382; https://doi.org/10.3390/diagnostics14040382
“Hepatoprotective Effects of Flavonoids against Benzo[a]Pyrene-Induced Oxidative Liver Damage along Its Metabolic Pathways”
by Min Kim, Seung-Cheol Jee and Jung-Suk Sung
Antioxidants 2024, 13(2), 180; https://doi.org/10.3390/antiox13020180
”Enhancing Liver Delivery of Gold Nanoclusters via Human Serum Albumin Encapsulation for Autoimmune Hepatitis Alleviation”
by Cong Meng, Yu Liu, Yuping Ming, Cao Lu, Yanggege Li, Yulu Zhang, Dongdong Su, Xueyun Gao and Qing Yuan
Pharmaceutics 2024, 16(1), 110; https://doi.org/10.3390/pharmaceutics16010110
“Hepatitis B Virus Reactivation with Immunosuppression: A Hidden Threat?”
by Sama Anvari and Keith Tsoi
J. Clin. Med. 2024, 13(2), 393; https://doi.org/10.3390/jcm13020393
“Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Viral Hepatitis: The Interlink”
by Cornelius J. Fernandez, Mohammed Alkhalifah, Hafsa Afsar and Joseph M. Pappachan
Pathogens 2024, 13(1), 68; https://doi.org/10.3390/pathogens13010068
“A Case Report: Idiopathic or Drug-Induced Autoimmune Hepatitis—Can We Draw a Line?”
by Dorotea Božić, Ante Tonkić, Jr,Katarina Vukojevic and Maja Radman
Clin. Pract. 2023, 13(6), 1393–1399; https://doi.org/10.3390/clinpract13060125
“Liver dECM–Gelatin Composite Bioink for Precise 3D Printing of Highly Functional Liver Tissues”
by Min Kyeong Kim, Wonwoo Jeong and Hyun-Wook Kang
J. Funct. Biomater. 2023, 14(8), 417; https://doi.org/10.3390/jfb14080417
“Viral Hepatitis: Diagnosis, Treatment and Management” |
“New Insights into Diagnosis and Therapeutic Strategies for Chronic Liver Diseases” |
![]() |
![]() |
“The Surveillance, Prevention, and Treatment of Viral Hepatitis: Looking Forward to Global Elimination” |
“Viral Hepatitis and Therapeutic Strategies” |
![]() |
![]() |
“Genetic Analysis of Hepatitis Virus Infection” |
“Oxidative Stress in Hepatic Diseases” |
![]() |
![]() |
“Viral Hepatitis Among Specific Populations: Epidemiology, Transmission, Treatment, and Prevention” |
“Biology of Liver Diseases” |
![]() |
![]() |
“Hepatitis E Virus (HEV) Infection Among Humans and Animals: Epidemiology, Clinical Characteristics, Treatment and Prevention—2nd Edition” |
“Human Hepatitis Viruses and Their Animal Homologues” |
![]() |
![]() |
“Advances in Hepatitis: Prevention, Treatment, and Global Health Impact” |
“Pathogenesis of Viral Hepatitis” |
![]() |
![]() |
“Liver Diseases: Diagnosis and Treatment in the Era of Personalized Medicine” |
“Gastrointestinal and Liver Diseases: New Advances in Diagnosis and Prognosis” |
![]() |
![]() |
15 July 2025
Meet Us at the X International Symposium on Advances in Synthetic and Medicinal Chemistry, 31 August–4 September 2025, Porto, Portugal

Conference: The X International Symposium on Advances in Synthetic and Medicinal Chemistry
Date: 31 August–4 September 2025
Location: Porto, Portugal
We are pleased to announce that MDPI will participate in the X International Symposium on Advances in Synthetic and Medicinal Chemistry (EFMC-ASMC 2025), to be held in Porto, Portugal, from 31 August to 4 September 2025.
This symposium will bring together chemists from around the world and will focus on the latest advances in strategies and methodologies across synthetic chemistry, medicinal chemistry, chemical biology, and drug discovery. We will present how we enable more sustainable processes and materials, alongside new opportunities to address challenging target classes with multiple success stories for clinical compounds.
MDPI is excited to participate in this prestigious event! Representing the journal of Pharmaceuticals (ISSN: 1424-8247), Prof. Dr. Amelia Rauter and Ms. Tatjana Beric will be present at the MDPI exhibition stand, where they will warmly welcome all scholars to stop by and engage in insightful discussions. This event presents a unique opportunity for participants to interact with leading experts in the field and explore potential collaborations. Do not miss the chance to visit our stand and exchange ideas with the MDPI editors and other delegates!
The following MDPI journals will be represented at the conference:
- Analytica;
- Chemistry;
- Sci. Pharm.;
- Medicines;
- Pharmaceuticals;
- Pharmaceutics;
- DDC;
- JPBI;
- BioChem;
- BioMed;
- Biophysica;
- Psychoactives;
- JNT;
- Anesthesia Research.
If you are planning to attend the conference, please feel free to start a conversation with us. We invite all conference attendees to visit MDPI’s booth and meet with our esteemed Editorial Board Members.
For more information about the conference, please visit the following website: https://www.efmc-asmc.org/.
14 July 2025
Pharmaceutics Webinar | Development of Physiologically Based Pharmacokinetic and Biopharmaceutics Analysis and Modeling (PBPK and PBBM), 22 July 2025

Physiologically Based Pharmacokinetic (PBPK) modeling involves simulating the absorption, distribution, metabolism, and excretion (ADME) of drugs throughout the body. So, PBPK modeling is a mathematical tool which can describe the drug concentration in an organism using compartments that correspond to the different tissues and takes into consideration the physiology of this organism to parameterize the model.
Physiologically Based Biopharmaceutics Modeling (PBBM) is an established analysis mechanistically linking in vitro drug product performance (like dissolution) to in vivo absorption and bioavailability.
These types of models have become useful in drug development since their discovery, and are particularly important in early phases, when in vitro data and physicochemical properties can be used to obtain plasma profiles, which would be later validated in vivo, and until the clinical development phases, in which simulations can be used to describe drug performance in special populations.
Date: 1:00 pm CEST | 7:00 am EDT | 7:00 pm CST Asia
Webinar ID: 815 2324 5665
Website: https://sciforum.net/event/Pharmaceutics-4
After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations made with academic institutional email addresses will be prioritized.
Unable to attend? Register anyway and we will let you know when the recording is available to watch online.
Register now for free!
Program:
Speaker/Presentation |
Time in CEST |
Prof. Dr. Isabel Gonzalez-Alvarez (Chair) Chair Introduction |
1:00–1:10 p.m. |
Dr. Bart Hens IVIVC development for a modified-release formulation using GPX™ software: impact of different deconvolution methods on dissolution safe space design |
1:10–1:40 p.m. |
Dr. Marival Bermejo In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan |
1:40–2:10 p.m. |
Dr. Yasuhiro (Hiro) Tsume PBPK modeling and PBBM analysis using GastroPlus™ |
2:10–2:40 p.m. |
Q&A Session |
2:40–2:50 p.m. |
Prof. Dr. Isabel Gonzalez-Alvarez Closing of Webinar |
2:50–2:55 p.m. |
Webinar Chair and Speakers:
- Prof. Dr. Isabel Gonzalez-Alvarez (Chair), Miguel Hernandez University, Pharmaceutics and Pharmaceutical Technology, Spain;
- Dr. Bart Hens, Drug Product Design Biomodeler/Biopharmaceutics Principal, Pfizer, United Kingdom;
- Dr. Marival Bermejo, Miguel Hernandez University, Pharmacokinetics and Pharmaceutical Technology, Spain;
- Dr. Yasuhiro (Hiro) Tsume, Merck Research Laboratories, New Jersey, United States of America.
9 July 2025
Interview with Dr. Zhengwei Huang—Winner of the Pharmaceutics Outstanding Reviewer Award

We are pleased to announce the winners of the Pharmaceutics Outstanding Reviewer Award—Dr. Dinesh Nyavanandi, Dr. Zhengwei Huang, and Dr. Mladena Lalić-Popović.
Name: Dr. Zhengwei Huang
Affiliation: College of Pharmacy, Jinan University, China
Research interests: inhalable nanomedicines; Drug delivery; ferroptosis; protein corona; biological fate
Below is a short interview with one of the winners—Dr. Zhengwei Huang:
1. Could you introduce yourself to our readers? What is your current research area?
I am Zhengwei Huang, an Associate Professor at Jinan University, China. The university is located in Guangzhou, China. I obtained my doctoral degree from the School of Pharmaceutical Sciences, Sun Yat-sen University, in 2020, with Prof. Chuanbin Wu (Fellow of the Royal Society of Chemistry) as my supervisor. Based on my year of graduation, it is clear that I am an early-career researcher. I have published over 50 papers in the field of drug delivery and nanomedicines and have an H-index of 21. I have also applied for eight Chinese patents, with five being issued. My current research areas include pulmonary drug delivery, anticancer nanoparticles, ferroptosis, and protein corona.
2. Which research topics do you think will be of particular interest to the research community in the coming years?
Currently, there are many studies on anticancer nanoparticles, a field in which I work. For example, there are liposomal, micellar, and inorganic nanoparticles, the aim of which is to treat various cancers like lung cancers, breast cancers, and gliomas. These studies are important to some degree. I believe, however, that nanomedicines for non-tumor diseases, such as diabetes, lung fibrosis, and Alzheimer’s disease, will be prioritized in the near future. I am eager to see more papers on these topics and am, in fact, witnessing an increasing number of such publications at the moment.
3. What factors motivate you to be a reviewer for Pharmaceutics?
Pharmaceutics is a flagship journal in its field, and I enjoy reading papers in it. It is worth noticing that it is a fully open access journal, which facilitates global and free communication of knowledge on drug delivery. From this perspective, it is a pleasant experience to work with such a journal. Thus, I am proud to take part in the reviewing process for this journal. Also, it is a great honor to be awarded a reviewer certificate from MDPI journals.
4. Could you please share with us your experience as a reviewer for Pharmaceutics?
As a reviewer, you are typically requested to perform the review within a week’s time. This is okay for me, as I wish to participate in a rapid turnaround. It turns out that the editorial process is quite rapid, as is the author response process. The review experience is smooth. Sometimes you will receive suggestions to improve the quality of your review reports, which are very useful. In addition, it is my honor to receive this award as an outstanding reviewer.
5. What are the key factors and aspects that you consider most when reviewing a manuscript?
The novelty of the study design and the quality of the figures. As the field of drug delivery grows rapidly, novelty is emphasized. Personally, if the paper presents an impressive idea, even if it is just a preliminary work, it may catch the eyes of reviewers. In contrast, if a paper is just repeating some ordinary experiments, the priority for publication may decrease. As for the quality of visual items, there is a saying that a figure says more than a thousand words. The schematic illustration needs to be well-designed, and the data charts should be well-presented.
6. What are your opinions about the scientific publication market, and what do you think about the open access model?
Of course, the scientific publication market is necessary and important. MDPI is a successful service provider in this market. Of note, the open access model facilitates the communication of recent studies, but it is not without costs. Some authors from developing countries or regions, or even some authors from developed ones, can be deterred from open access publishing owing to financial stress. Thus, if there were more funding opportunities from various parties to help cover the APC, the development of the open access model would be further boosted.
Many thanks to MDPI, firstly. I would like to acknowledge Prof. Chuanbin Wu and Prof. Xin Pan, two senior scientists who are showing me the way in pharmaceutics research. Prof. Wu was my PhD supervisor, who showed me the way to develop my career. Prof. Pan is my senior colleague who inspired me a lot in my research topics. In addition, I would like to thank Dr. Wenhao Wang for his exciting experimental work.
4 July 2025
MDPI’s Newly Launched Journals in June 2025
Six new journals covering a range of subjects launched their inaugural issues in June 2025. We are excited to be able to share with you the newest research rooted in the value of open access. We are pleased to present the latest research and to make it accessible to all.
We extend our sincere thanks to all the Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.
Please feel free to browse and discover more about the new journals below.
Journal | Founding Editor-in-Chief | Journal Topics (Selected) |
![]() |
Prof. Dr. Chang-Pu Sun, China Academy of Engineering Physics, Beijing, China; Computational Science Research Center, China Editorial | View inaugural issue |
quantum information and phenomena; condensed matter physics and statistical physics; atomic, molecular, and optical physics; computational physics and mathematical methods View journal scope | Submit an article |
![]() |
Prof. Dr. Hualiang Lin, Sun Yat-sen University, China; Prof. Dr. Jose L. Domingo, Universitat Rovira i Virgili, Spain Editorial | View inaugural issue |
green and organic food; green infrastructures; green exercise; environmental impact of the healthcare sector; effects of climate change on human health | View journal scope | Submit an article |
![]() |
Prof. Dr. Francesco Veglio, University of L’Aquila, Italy Editorial | View inaugural issue |
ultra-pure substances; water purification; air purification; gas purification; inorganic chemical purification; purification technologies View journal scope | Submit an article |
![]() |
Prof. Dr. Junxing Zheng, Huazhong University of Science and Technology, China Editorial | View inaugural issue |
computer-aided design and engineering; artificial intelligence and machine learning; building information modeling (BIM) and digital twins; robotics and automation in construction; smart sensors and Internet of Things (IoT); intelligent control systems and facilities management View journal scope | Submit an article |
![]() |
Prof. Dr. Assunta Di Vaio, University of Naples Parthenope, Italy Editorial | View inaugural issue |
sustainability, managerial, and biodiversity accounting; carbon management accounting; corporate social responsibility; artificial intelligence and disclosure View journal scope | Submit an article |
![]() |
Prof. Dr. Changjun Liu, Sichuan University, China Editorial | View inaugural issue |
bioeffects of electromagnetic waves; electromagnetic science and engineering; microwave, millimeter-wave, and terahertz technologies; metamaterials and metasurfaces; communication, sensing, and networks; energy, power, and sustainable applications; quantum and emerging technologies; artificial intelligence and advanced fabrication View journal scope | Submit an article |
2 July 2025
MDPI INSIGHTS: The CEO's Letter #24 - 2024 Impact Factor & CiteScore, MDPI Summits France & USA, Tu Youyou Award

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI’s 2024 Impact Factor Highlights
For those of our readers who are new to academic publishing, you may have heard some news in June around the Impact Factor release. Every year, typically in June, Clarivate releases its annual Journal Citation Reports (JCR), which include Journal Impact Factors (JIF). This metric is widely used in academic publishing to reflect the average number of citations received by recent articles in each journal.
While Impact Factor is just one of many indicators of journal influence, it remains a major milestone for authors, editors, and publishers. It’s used to assess journal visibility, researcher recognition, and scholarly reach. Throughout our international meetings and events, it’s clear that the Impact Factor is something many of our authors and editorial board members care about, as it can influence where they choose to submit an article and the funding they receive for their research.
“These results reflect the trust that the scholarly community places in MDPI”
MDPI’s 2024 Impact Factor Highlights
- 298 MDPI journals received a Journal Impact Factor.
- 60 journals earned their first-ever Impact Factor
- To put this in perspective: MDPI’s 60 new journal acceptances into the Web of Science was the second highest number of any publisher in 2024, behind Elsevier and ahead of Springer Nature. Our 87% acceptance rate for journals submitted to Web of Science shows the strength of our editorial process and our proven ability to develop journals aligned with Clarivate’s 24 evaluation criteria.
- Notably, Textiles, Mathematics, International Journal of Neonatal Screening, Smart Cities, Systems, and Pharmaceutics ranked in the top 10% in their respective categories, highlighting their growing influence and prestige within their academic fields. This shows that high-quality indexing goes beyond visibility; it upholds credibility and trust.
- 193 MDPI journals are now ranked in the top 50% (Q1/Q2) of their subject categories.
- What does this mean, and why is it important? Journals are ranked by quartiles within their field, based on their Impact Factor. Q1 represents the top 25% of journals in their category, Q2 the next 25%, and so on. Being in Q1 or Q2 shows that a journal is performing well relative to other journals in its category. Authors and institutions often look at quartile rankings when choosing where to publish – it’s an important indicator of visibility and recognition, within its respective category.
- 116 of our previously ranked journals increased their Impact Factor.
- 14 MDPI journals achieved an Impact Factor of 5.0 or higher, suggesting a high degree of influence and visibility.
These results reflect our staff's hard work: from our editorial and production teams to our indexing, communications, and data teams, and beyond. This also reflects the trust that the scholarly community places in MDPI, reinforcing the message that when researchers publish with MDPI, they publish with impact.
Open Access with Impact
As the leading fully open access publisher, our journals have received a total of 18.4 million citations in the Web of Science by the end of 2024, reflecting the growing reach and engagement of research published with MDPI. We are committed to making scientific research freely accessible to everyone, everywhere. With the support of more than 4.2 million contributing authors, we’re proud to support the global shift toward open access.
Further Reading
If you’d like to better understand how journals get indexed and why Impact Factors matter, please read this recent interview with Dr. Constanze Schelhorn (Head of Indexing). It gives you a behind-the-scenes look at the role our indexing team plays in supporting journal indexing and visibility.
You can also read our official news announcement shared last week: MDPI Journals in the 2024 Journal Citation Reports.
Thank you to everyone, from our authors and reviewers to our editors and internal teams, who contributed to the progress of our journal indexing in 2024. We’re continuing to build journals that are recognized and trusted across disciplines.
Impactful Research
MDPI Journals See Continued Growth in 2024 CiteScore Results
Continuing our indexing updates, I’m pleased to share that MDPI has achieved strong results in the latest CiteScore metrics, released on 5 June by Scopus. These results reflect the collective efforts of our editors, reviewers, authors, and internal teams, with their dedication to quality and visibility in scientific publishing. You can read the full announcement here.
2024 Highlights:
- 322 MDPI journals received a CiteScore (up from 274 last year).
- 283 journals (88%) are ranked in Q1 or Q2 of their subject categories.
- 237 journals (85%) saw an increase in their CiteScore compared to last year.
- 48 journals received a CiteScore for the first time.
- 39 journals are now placed in the top 10% of their subject areas.
“This growth highlights our commitment to supporting open, trusted science”
What is CiteScore and how is it measured?
CiteScore metrics are developed by Elsevier as an alternative to the Impact Factor. They measure the citation impact of journals and can be accessed freely on Scopus. The metric represents the yearly average number of citations to recent articles published in a journal. If you’re interested in learning more about citation metrics and how we use them, check out this blog post.
Why is this important?
These results show the growing recognition for, and impact of, MDPI journals across disciplines. CiteScore rankings help researchers, institutions, and funders assess where high-quality work is being published. This growth improves our journals’ positioning in the publishing landscape and highlights our commitment to supporting open, trusted science.
Inside MDPI
Highlights from the MDPI USA Summit in Boston (5–6 June)
With several Summits already behind us, I think this is a good time to reflect on the purpose of these Summits.
Why do we organize MDPI Summits?
These one-and-a-half-day, invite-only gatherings are designed to improve our relationships with Chief Editors who lead our journals and are respected voices in their fields. The Summits aim to:
- Share MDPI’s values, achievements, editorial practices, and local market collaborations.
- Collect feedback on MDPI operations and journal practices.
- Empower Chief Editors to confidently represent MDPI beyond the Summit.
While Chief Editors know their journals well, these events help them better understand MDPI. We want them to be ambassadors for our brand. The aim is for them to walk away informed, engaged, and equipped to share positively about MDPI.
|
|
|
About the Boston Summit
Held on 5–6 June, our first USA Summit gathered over 25 Chief Editors to learn more about MDPI’s activities and collaborations in the USA. The program included presentations, Q&A, and a panel discussion.
Agenda Highlights:
Moderated by Summer Huggard (Operations Manager [Toronto], MDPI), the program featured:
- MDPI Overview and USA Collaboration – Stefan Tochev (CEO, MDPI)
- AI in Publishing and MDPI's Actions – Feichi Lu (Junior Data Scientist, MDPI)
- MDPI Editorial Process and Research Integrity – Dr. Giulia Stefenelli (Scientific Communications Lead, MDPI)
- Panel Discussion – Stefan, Feichi, Giulia, Claudia
- Society Partnerships – Dr. Clàudia Aunós (Society Partnerships Senior Manager, MDPI)
- Voice of the Customer and Closing Remarks – Stefan Tochev (CEO, MDPI)
|
|
|
|
|
|
MDPI & the USA: Facts and Figures
- With over 216,000 publications, the USA is MDPI’s second-largest contributor after China.
- In 2024, the USA ranked 2nd in total submissions and 2nd in total MDPI publications, with more than 28,200 publications.
- As of 2020, the cumulative number of authors from the USA until April 2025 was 352,099.
- As at April 2025, there are more than 12,035 active Editorial Board Members (EBMs) from the USA, with 55% having an H-index over 26.
- Among them, 96 serve as Editors-in-Chief (EiC) and 218 as section-Editors-in-Chief (SEiC)
- MDPI has more than 920 Institutional Open Access Program agreements worldwide, with over 130 from the USA.
A special thanks to our Toronto team, and everyone who worked behind the scenes to make this event run smoothly.
Coming Together for Science
Highlights from the MDPI France Summit in Paris (12–13 June)
We completed our first MDPI France Summit in Paris last week, and it was a special event. Attendees were engaged from beginning to end, remaining after hours to network and collaborate.
|
|
|
Why a France Summit?
We chose to host a France Summit in view of the recent challenges MDPI has faced with the National Centre for Scientific Research (CNRS). What we took away from the event is that our authors and editors very much appreciate and enjoy working with us, but we need to address the concerns raised by CNRS, around Article Processing Charges (APCs) and the funding of gold open access publications.
“Our authors and editors very much enjoy working with us”
Some of the claims made in the June 2023 interview with Alain Schuhl, the Deputy CEO for Science at the CNRS, are simply not factual. For example, they state that MDPI’s “average APC charges per article are now around the same as Springer Nature’s.” Here is the relevant passage, reproduced verbatim:
This is not accurate.
A recent preprint analysing APC data from Elsevier, Springer Nature, Wiley, PLOS, MDPI, and Frontiers (2019–2023) shows that MDPI’s average APCs remain significantly lower than those of Springer Nature and several other major publishers.
The MDPI Summits are part of our outreach and communication efforts to address misconceptions and clarify MDPI’s position as one of the most accessible and affordable major gold open access publishers in the world.
Summit Overview
Held on 12–13 June, the France Summit gathered over 20 Chief Editors to learn more about MDPI’s activities and collaborations in France. Many of these editors are influential in their institutions and professional societies. Several also have connections to CNRS, which makes this an important opportunity to clarify how we operate and build trust through open and transparent communication and hopefully turn our editors into informed advocates of MDPI.
Summit Feedback
The feedback has been very positive, with most attendees completing the post-event survey and all rating the experience as Excellent or Good. A few highlights:
- “The whole thing was highly professional and, above all, provided quantified details that will allow us to better answer questions surrounding MDPI.”
- “The summit was an opportunity to meet personally various people directly engaged in the organization and policies of MDPI, which made it possible to clarify some important points concerning publishing with MDPI.”
- “Very well organized! A great opportunity to see all French MDPI partners and editors.”
Program Highlights:
Moderated by Miruna Adelina Nicolcioiu (Senior Conference Producer), the program featured:
- MDPI Overview and France Collaboration – Stefan Tochev (CEO)
- MDPI Editorial Process and Peer-Review Quality – Dr. Marta Colomer (Public Affairs Specialist)
- Institutional Partnerships and Open Access Funding Models – Becky Castellon (Institutional Partnerships Manager)
- AI in Publishing and MDPI's Actions – Daniele Raimondi (Data Scientist)
- Publication Ethics: Global Trends – Diana Cristina Apodaritei (Research Integrity Specialist)
- Closing Remarks – Stefan Tochev
- Panel Discussion – Diana, Becky, Prof. Dr. Patrick Da Cost, and Stefan
|
|
|
|
|
|
MDPI & France: Facts and Figures
- With over 51,000 publications, France is MDPI's tenth-largest contributor, and fifth largest among EU countries after Italy, Spain, Germany, and Poland.
- As of 2020, the cumulative number of authors from France until April 2025 was 87,592.
- As at April 2025, there are more than 2,800 active Editorial Board Members (EBMs) from France, with 59% having an H-index over 26.
- Among them, 22 serve as Editors-in-Chief (EiC) and 61 as section-Editors-in-Chief (SEiC)
- In 2024, IJMS, JCM, and Molecules were the top three MDPI journals in terms of submissions from French-affiliated authors.
Special thanks to our colleagues from Romanian offices for organizing this successful event.
Closing Thoughts
Richard DiMarchi and Rolf Müller Share the 2024 Tu Youyou Award
As we wrap up this month’s newsletter, I’d like to take a moment to recognize the winners of the 2024 Tu Youyou Award, presented by our journal Molecules. I am pleased to share that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.
I invite you to read the editorial co-authored by the Tu Youyou Award Committee, which highlights the significance of the award and the remarkable impact of the recipients’ research.
A sincere thank-you to the 2024 Award Committee for their dedication and selection process, and congratulations once again to this year’s honourees. Your work exemplifies the kind of research MDPI is proud to support and amplify.
About the Tu Youyou Award For further information about the award and the winners, please visit the Tu Youyou Award website. |
Chief Executive Officer
MDPI AG
1 July 2025
Meet Us at the CRS 2025 Annual Meeting and Exposition, 14–18 July 2025, Philadelphia, USA

Conference: The CRS 2025 Annual Meeting and Exposition
Date: 14–18 July 2025
Location: Philadelphia, USA
This conference will be the 52nd annual conference of the Controlled Release Society. The annual CRS conference is the most important conference in the pharmaceutics field. The main topics of the conference include nanomedicine and nanoscale delivery, immuno delivery, oral delivery, skin and mucosal delivery, ocular delivery, bioengineering, gene delivery and gene editing, alternative methods to animal testing, long-acting drug delivery formulations, delivery to the nervous system, artificial intelligence, and predictive models in pharmaceutical technologies.
The following open access journals will be represented at the event:
- Pharmaceutics;
- Gels;
- Pharmaceuticals;
- Biomedicines;
- Bioengineering;
- Biomolecules;
- Sci. Pharm;
- CIMB;
- Future Pharmacology.
If you plan to attend this conference, please contact us online. Our delegates look forward to meeting you in person at booth #202 and answering any questions you may have. For more information about the conference, please visit the following website: https://crs2025annualmeeting.eventscribe.net.
28 June 2025
Meet Us at the 17th Academic Conference of the Chinese Pharmacological Society, 22–26 July 2025, Xiong An, China

Conference: The 17th Academic Conference of the Chinese Pharmacological Society
Date: 22–26 July 2025
Location: Xiong An, China
MDPI will be attending the 17th Academic Conference of the Chinese Pharmacological Society as an exhibitor, which will be held from 22 to 26 July 2025. We welcome researchers from diverse backgrounds to attend and share their latest ideas with us.
The year 2025 marks the 40th anniversary of the establishment of the Chinese Pharmacological Society. We are pleased to attend the conference, which will systematically summarize the experience of the Chinese Pharmacological Society’s construction and development over the past 40 years. The 17th Academic Conference of the Chinese Pharmacological Society serves as an interdisciplinary forum for the prompt exchange of recent achievements, experiences, theories, technologies, and methods in China's pharmacology research domain, in addition to new drug development and related fields, The conference will promote the innovative development of China's pharmacology research and new drug development on a longer-term basis. Your participation will significantly contribute to the medical discourse and enhance the conference’s impact within the pharmacological field.
The following MDPI journals will be represented at the conference:
- Biomedicines;
- Future Pharmacology;
- Pharmacy;
- Immuno;
- Marine Drugs;
- Pharmaceutics;
- Pharmacoepidemiology;
- Vaccines;
- JPBI.
If you are planning to attend the above conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person at the booth and answering any questions that you may have. For more information about the conference, please visit the following website: https://mm.sciconf.cn/cn/web/index/29613?pc=1.
25 June 2025
Pharmaceutics Receives an Updated Impact Factor of 5.5

We are pleased to share that Pharmaceutics (ISSN: 1999-4923) was awarded an increased Impact Factor of 5.5 in the 2024 Journal Citation Reports™ released by Clarivate™ in June 2025. Pharmaceutics ranks in Q1 (34 among 352, Top 10%) in the JCR category of the “Pharmacology and Pharmacy” category.
The 2024 Journal Impact Factor is calculated by dividing the number of citations received in 2024 to all publications in the journal from 2022 and 2023 by the total number of citable publications from those same years.
To learn more, visit our journal statistics website for detailed metrics or check out our news article for general information.
The support and dedication of all the editors, reviewers, authors, and readers are an integral part of the journal’s performance. We would like to take this opportunity to thank all of you who have contributed to the journal.
16 June 2025
Pharmaceutics Receives an Increased CiteScore of 10.0

We are pleased to share that Pharmaceutics (ISSN: 1999-4923) has received an updated CiteScore of 10.0 in June 2025. The CiteScore ranks the journal 22nd out of 185 titles (Q1) in the “Pharmaceutical Science” category, an impressive achievement for a journal running in Volume 17.
You can find more statistics on https://www.mdpi.com/journal/pharmaceutics/stats.
The current CiteScores measure the average number of citations within a journal over a four-year window (2021–2024). The Scopus database provides a comprehensive suite of metrics that support informed publishing strategies, research evaluation and enable benchmarking of journal performance.
This achievement reflects the collective efforts of our authors, reviewers, and editors. Together we will continue to track the progress of Pharmaceutics and its growing impact in pharmaceutical formulation, process development, drug delivery, pharmacokinetics, biopharmaceutics, pharmacogenetics, and interdisciplinary research involving, but not limited to, engineering, biomedical sciences, and cell biology.